Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.74 |
| ▸ | VDR | P11473 | 4/20 | 0.74 |
| ▸ | MEN1 | O00255 | 3/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.74 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.74 |
| ▸ | CDC25A | P30304 | 3/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.74 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.74 |
| ▸ | PGR | P06401 | 2/20 | 0.74 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.74 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.74 |
| ▸ | HPGD | P15428 | 1/20 | 0.74 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.74 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.74 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.74 |
| ▸ | DRD3 | P35462 | 1/20 | 0.74 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8003899 | 1.00 | MAPT (0.74) | MAPTVDRMEN1KMT2AADORA3 | |
| SCHEMBL10034122 | 1.00 | MAPT (0.74) | MAPTVDRMEN1KMT2AADORA3 | |
| SCHEMBL4960177 | 0.93 | MAPT (0.74) | MAPTVDRMEN1KMT2AADORA3 | |
| SCHEMBL9330205 | 0.91 | MAPT (0.71) | MAPTVDRMEN1KMT2AADORA3 | |
| SCHEMBL352251 | 0.90 | MAPT (0.75) | MAPTVDRMEN1KMT2AADORA3 | |
| SCHEMBL6403771 | 0.90 | MAPT (0.75) | MAPTVDRMEN1KMT2AADORA3 | |
| SCHEMBL3824860 | 0.90 | MAPT (0.70) | MAPTVDRMEN1KMT2AADORA3 | |
| SCHEMBL3220709 | 0.90 | MAPT (0.70) | MAPTVDRMEN1KMT2AADORA3 | |
| SCHEMBL16782349 | 0.89 | MAPT (0.67) | MAPTVDRMEN1KMT2AADORA3 | |
| SCHEMBL3698818 | 0.89 | MAPT (0.69) | MAPTVDRMEN1KMT2AADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1276 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230135029-A1 | COMPOSITIONS AND METHODS FOR INCREASING DIGESTIBILITY OF CALCIUM AND PHOSPHOROUS IN PIGS | PREMEX INC (US) | 2023-05-04 | — | — | US | claimed |
| CN-110208435-B | Method for simultaneously detecting content of 25-hydroxyvitamin D3 and 25-hydroxyvitamin D2 in human peripheral blood | 北京和合医学诊断技术股份有限公司 | 2023-03-24 | — | — | CN | claimed |
| EP-3600431-B1 | A COMBINATION FOR USE IN THE TREATMENT OF LUNG CANCER | LDN PHARMA LTD (GB) | 2022-11-23 | — | — | EP | claimed |
| US-11413253-B2 | Nanoparticle delivery systems | CELATOR PHARMACEUTICALS, INC. (US) | 2022-08-16 | — | — | US | claimed |
| CN-114755323-A | Method and kit for detecting content of fat-soluble vitamins in dried blood paper | 北京和合医学诊断技术股份有限公司 | 2022-07-15 | — | — | CN | claimed |
| CN-114460314-B | Multivitamin D analogue detection kit and detection method | 普迈德（北京）科技有限公司 | 2022-06-24 | — | — | CN | claimed |
| CN-114460314-A | Detection kit and detection method for multivitamin D analogues | 普迈德（北京）科技有限公司 | 2022-05-10 | — | — | CN | claimed |
| EP-3986154-A1 | FEED ADDITIVE FOR REDUCING SOMATIC CELL COUNT | DSM IP Assets B.V. (NL) | 2022-04-27 | — | — | EP | claimed |
| US-20220124572-A1 | PHARMACEUTICAL COMPOSITIONS | JOYDERMA AG (CH) | 2022-04-21 | — | — | US | claimed |
| CN-107920985-B | Improved nanoparticle delivery system | 塞拉特药物股份有限公司 | 2022-03-01 | — | — | CN | claimed |
| WO-1995013062-A1 | BUTYRIC ESTER CYTO-DIFFERENTIATING AGENTS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1995-05-18 | — | — | WO | claimed |
| US-5352781-A | Process for precursors to calcitriol and related compounds | HOFFMANN-LA ROCHE INC. (US) | 1994-10-04 | — | — | US | claimed |
| EP-0587751-A1 | THERAPEUTIC COMPOSITIONS FOR OSTEOINDUCTION | THE PROCTER & GAMBLE COMPANY (US) | 1994-03-23 | — | — | EP | claimed |
| EP-0544391-A1 | Compositions for topical treatment of psoriasis and atopic dermatitis | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1993-06-02 | — | — | EP | claimed |
| EP-0129003-B2 | COSMETIC AND DERMATOLOGICAL COMPOSITIONS CONTAINING 1-ALPHA-HYDROXYCHOLECALCIFEROL | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1993-02-24 | — | — | EP | claimed |
| WO-1992021365-A1 | THERAPEUTIC COMPOSITIONS FOR OSTEOINDUCTION | THE PROCTER & GAMBLE COMPANY (US) | 1992-12-10 | — | — | WO | claimed |
| EP-0301167-B1 | A COMBINATION OF CHOLECALCIFEROL DERIVATIVES FOR THE TREATMENT OF RENAL BONE DISEASE | Teva Pharmaceutical Industries Limited (IL) | 1992-08-19 | — | — | EP | claimed |
| US-4997824-A | Bone disorders | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1991-03-05 | — | — | US | claimed |
| EP-0398715-A2 | Method of exterminating rodents and other vertebrate pests | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1990-11-22 | — | — | EP | claimed |
| EP-0301167-A1 | A combination of cholecalciferol derivatives for the treatment of renal bone disease | Teva Pharmaceutical Industries Limited (IL) | 1989-02-01 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11413253-B2 | Nanoparticle delivery systems | PAICS, ABCB1, TSG101 | MAPT 1574/4885VDR 2622/4885MEN1 2222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.